Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report from India observed that short-term cabergoline treatment brought clinical and biochemical remission in a 12-year-old with persistent Cushing disease after surgery and radiotherapy.

This study reports a novel LC/MS method that separates and analyzes all known ceramide subclasses in human stratum corneum, identifying a new subclass, CER [EOdS], with minimal sample preparation.

This study found that watercress extract may help treat hair loss by increasing RSPO1 secretion and decreasing DKK1 secretion, improving hair thickness and density in clinical trials.

This study reports that in mice, CaR plays a critical role in sensing the epidermal Ca2+ gradient, influencing keratinocyte differentiation, and affecting epidermal development.

In this study, 60 mg/day of Cepharanthine significantly reduced the time to a negative COVID-19 test among de novo infected patients with good compliance, though 120 mg/day showed no such effect.

This summary reflects on the success of the Health Education England stakeholder summit on non-surgical cosmetic interventions and outlines future training plans without reporting new research results.

This article discusses the potential of intralesional cidofovir for treating SCC without systemic toxicity, noting that surgical excision remains the best treatment option; it reports no new clinical results.

In this study, adults with persistent facial erythema of rosacea showed significantly greater improvement when treated with once-daily oxymetazoline cream compared to a vehicle, and using baseline photographs in assessments enhanced the accuracy by reducing perceived vehicle effects.

This study found that a 16-week dermal application of rice bran extract significantly increased hair density and diameter in male androgenic alopecia patients without causing adverse reactions.

The study aims to find the best treatment for central serous chorioretinopathy by comparing various options.

This review discusses the complex pathophysiology of polycystic ovary syndrome and reports no clinical trial results, emphasizing the need for better understanding to improve treatment options.

In this phase I study, CT-707, a new ALK inhibitor, showed a 77% response rate among Chinese patients with advanced ALK-rearranged non-small cell lung cancer, suggesting clinical effectiveness despite some adverse events like diarrhea and liver enzyme elevation.

This source reported that patients who initially responded to ritlecitinib treatment showed sustained hair regrowth through week 48, with up to one-third of those not meeting target efficacy at week 24 also achieving a response with continued treatment.

This study established a rapid and accurate ultra-performance liquid chromatographic method for chemical fingerprinting and analyzing Platycladi cacumen, effectively distinguishing batches based on geographical and climatic conditions.

This study suggests that supplementing with a cell-free fat extract might enhance embryo development and improve clinical outcomes in older women experiencing in vitro fertilization failure.

This study in a nine-year-old boy from Lebanon identified a gene mutation (c.1066dup p.(Arg356Profs*16)) associated with a rare inborn error of immunity, characterized by craniosynostosis, jaundice, and several other symptoms, expanding the known genotypic and phenotypic spectrum of this condition.

This study found that ROR2 plays a crucial role in the regulation of hair follicle stem cell self-renewal and maintenance, particularly by compensating for the absence of β-catenin.

This study evaluated the long-term safety of ritlecitinib in adolescents with alopecia areata and found it to be well-tolerated without new safety concerns over approximately five years, with common adverse events including positive SARS-CoV-2 tests, acne, headache, and nasopharyngitis.

This paper reports insights from an Expert Panel convened by the Society for Immunotherapy of Cancer on managing immune-related adverse events (irAEs) following immune checkpoint inhibitor therapy, highlighting surveillance gaps and the need for a comprehensive irAE registry to improve post-treatment care for cancer survivors.

This study demonstrated that CEP may effectively treat pulmonary fibrosis by inhibiting fibroblast activation through regulating macrophage M2 polarization and decreasing fibrosis-associated factors, suggesting a new avenue for future research in this area.

This article reviews advancements in carbon dots for tissue engineering and regenerative medicine, highlighting challenges and future directions without presenting new clinical findings.

This study defines two types of RDEB wounds, chronic open and recurrent, and finds that patient self-reports on wound size correlate well with investigator measurements when complemented by serial photography.

Reflectance confocal microscopy can tell apart white dots on the scalp as either sweat gland ducts or hair follicle openings.

This study suggests that RORα, RORβ, and RORγ mRNA expression in cashmere goat skin is related to different stages of hair follicle development, indicating a possible role in cycled cashmere growth.

In this study, the combination of ECM-C with microneedle and radiofrequency treatments improved periorbital wrinkles, skin elasticity, and thickness more effectively than ECM-C with microneedles alone, but subjective evaluations showed no significant differences.

This case series describes Erythromelanosis follicularis faciei et colli in five Indian patients, suggesting it may be more common than currently reported.

This study found that ritlecitinib, approved for alopecia areata in patients aged 12 and older, has an acceptable safety profile with mild to moderate side effects and no increase in serious adverse events compared to placebo.

RCS-01 is safe and may help rejuvenate aging skin.

This conference proceedings compilation from Prague covers global trends, problems, and solutions in science, engineering, and technology, but reports no new clinical results.

This study observed that most patients with alopecia areata experienced sustained scalp hair regrowth after 48 weeks of ritlecitinib treatment, with safety consistent with prior findings.